Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRK NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$87.54+0.4%$84.43$73.31▼$106.49$217.76B0.3712.27 million shs7.90 million shsSMMTSummit Therapeutics$19.28+2.8%$21.72$15.55▼$36.91$13.96B-1.133.74 million shs3.77 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+0.33%+3.25%+9.94%+3.20%-17.71%SMMTSummit Therapeutics+2.83%-8.15%-5.95%-32.75%-3.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$87.54+0.4%$84.43$73.31▼$106.49$217.76B0.3712.27 million shs7.90 million shsSMMTSummit Therapeutics$19.28+2.8%$21.72$15.55▼$36.91$13.96B-1.133.74 million shs3.77 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+0.33%+3.25%+9.94%+3.20%-17.71%SMMTSummit Therapeutics+2.83%-8.15%-5.95%-32.75%-3.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.30Hold$104.3319.19% UpsideSMMTSummit Therapeutics 2.50Moderate Buy$31.1461.53% UpsideCurrent Analyst Ratings BreakdownLatest SMMT and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/25/2025SMMTSummit TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.0010/21/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.0010/21/2025SMMTSummit TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$13.00 ➝ $16.0010/20/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.0010/20/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.0010/13/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$84.00 ➝ $95.0010/13/2025SMMTSummit TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/8/2025MRKMerck & Co., Inc.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025SMMTSummit TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$63.62B3.44$9.50 per share9.21$18.33 per share4.78SMMTSummit Therapeutics$700K20,504.00N/AN/A$0.26 per share74.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.4913.498.840.9625.79%41.05%16.55%10/30/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.24N/AN/AN/AN/A-311.15%-262.35%N/ALatest SMMT and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025MRKMerck & Co., Inc.$2.37N/AN/AN/A$17.00 billionN/A10/20/2025Q3 2025SMMTSummit Therapeutics-$0.14-$0.31-$0.17-$0.31$77.16 millionN/A8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.70%N/A49.92%14 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.691.421.17SMMTSummit TherapeuticsN/A3.805.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.13%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.50 billion2.49 billionOptionableSMMTSummit Therapeutics110744.44 million112.41 millionOptionableSMMT and MRK HeadlinesRecent News About These CompaniesInsiders Are Scooping Up Shares of a Miner, a Driller, and a BiotechOctober 25 at 8:45 AM | 247wallst.comCantor Fitzgerald Analysts Lower Earnings Estimates for SMMTOctober 25 at 2:17 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Director Buys $9,999,982.58 in StockOctober 24 at 10:42 PM | marketbeat.comMahkam Zanganeh Buys 26,680 Shares of Summit Therapeutics (NASDAQ:SMMT) StockOctober 24 at 4:45 PM | marketbeat.comRobert Duggan Purchases 26,680 Shares of Summit Therapeutics (NASDAQ:SMMT) StockOctober 24 at 4:45 PM | marketbeat.comXia Yu, director at Summit Therapeutics, buys $9.9 million in sharesOctober 24 at 11:51 AM | investing.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 26,680 SharesOctober 24 at 5:49 AM | insidertrades.comCantor Fitzgerald Has Weak Forecast for SMMT FY2025 EarningsOctober 23 at 6:57 AM | marketbeat.comHC Wainwright Has Negative Forecast for SMMT FY2025 EarningsOctober 23 at 6:57 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?October 22 at 12:09 PM | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at GuggenheimOctober 22 at 10:02 AM | marketbeat.comSA analyst upgrades/downgrades: TSLA, MSFT, AAPL, SMMTOctober 21, 2025 | msn.comSMMT's Q3 Loss Wider Than Expected, Stock Down on Study AmendmentsOctober 21, 2025 | zacks.comSummit Therapeutics price target lowered to $32 from $33 at Clear StreetOctober 21, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Announces Quarterly Earnings ResultsOctober 21, 2025 | marketbeat.comSummit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call TranscriptOctober 20, 2025 | seekingalpha.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's WhyOctober 20, 2025 | marketbeat.comSummit's Bold BLA Without Stat-Sig OS: Why I Step Back To HoldOctober 20, 2025 | seekingalpha.comSummit Therapeutics Inc. 2025 Q3 - Results - Earnings Call PresentationOctober 20, 2025 | seekingalpha.comSummit Therapeutics Sees Unusually High Options Volume (NASDAQ:SMMT)October 20, 2025 | marketbeat.comSummit Therapeutics' (SMMT) "Market Outperform" Rating Reaffirmed at JMP SecuritiesOctober 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT and MRK Company DescriptionsMerck & Co., Inc. NYSE:MRK$87.54 +0.36 (+0.41%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$87.72 +0.18 (+0.21%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Summit Therapeutics NASDAQ:SMMT$19.28 +0.53 (+2.83%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$19.40 +0.12 (+0.62%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
